Phase III, Multi-center, Randomized, 12-week, Double-blind, Parallel-group, Placebo-controlled Study to Evaluate the Efficacy and Safety of RO4917838 in Patients With Sub-optimally Controlled Symptoms of Schizophrenia Treated With Antipsychotics Followed by a 40-week Double-blind, Parallel-group, Placebo-controlled Treatment Period.
Phase III, Multi-center, Randomized, 12-week, Double-blind, Parallel-group, Placebo-controlled Study to Evaluate the Efficacy and Safety of RO4917838 in Patients With Sub-optimally Controlled Symptoms of Schizophrenia Treated With Antipsychotics Followed by a 40-week Double-blind, Parallel-group, Placebo-controlled Treatment Period.
This randomized, multi-center double-blind, parallel-group, placebo-controlled study will evaluate the efficacy and safety of RO4917838 (bitopertin) in patients with sub-optimally controlled symptoms of schizophrenia. Patients, on stable treatment with antipsychotics, will be randomized to receive daily oral doses of RO4917838 or matching placebo for 52 weeks, followed by an optional treatment extension for up to 3 years.
Inclusion Criteria:
Exclusion Criteria:
GuangzhouGuangdong, 510370, China
Praha 8 - Bohnice, 181 03, Czechia
Funabashi-shi, 273-8540, Japan
Gunma, 370-2455, Japan
Hokkaido, 060-8648, Japan
Kanzaki-gun, 842-0192, Japan
Kitakyushu-shi, 807-8556, Japan
Koshi-shi, 861-1116, Japan
Kurayoshi-shi, 682-0023, Japan
Omuta-shi, 836-0004, Japan
Shirakawa-shi, 961-0021, Japan
Toyoake-shi, 470-1192, Japan